Skip to main content
. Author manuscript; available in PMC: 2008 Sep 1.
Published in final edited form as: Cell Metab. 2007 Sep;6(3):164–179. doi: 10.1016/j.cmet.2007.07.001

Table 2.

Quantitative trait loci for atherosclerosis in inbred mouse crosses

Chr Crossa markerb cM (CI)c Mb (CI)d LODe locus Reference
1 B × H and C × B RI lines D1Mit159 82 162 (151–170) Ath1 (Paigen et al., 1987c; Phelan et al., 2002)
(B6 × A) F2 1–169 Mb 100 178 (169–195) 3.4 Ishimori et al, unpublished
(B6.129-Apoe−/− × FVB.129-Apoe−/−) F2 D1Mit359 100 178(169–195) 3.3 Ath9 (Dansky et al., 2002)
2 (PERA × B6.129-Ldlr−/−) × B6.129-Ldlr−/− D2Mit405 69 148 (117–152) 2.8 Athla1 (Bretschger Seidelmann et al., 2005)
(AKR.129-Apoe−/− × DBA/2.129-Apoe−/−) RpF2 rs13476938 107 179 (174–179) 3.3 Ath28 (Smith et al., 2006)
3 (AKR.129-Apoe−/− × DBA/2.129-Apoe−/−) RpF2 rs13477166 33 67 (53–89) 2.7 Ath23 (Smith et al., 2006)
(B6.129-Ldlr−/− × FVB.129-Ldlr −/−) F2 D3Mit57 55 119 (90–131) 4.1 Ascla4 (Teupser et al., 2006)
(FVB.129-Ldlr −/− × B6.129-Ldlr −/−) F2 D3Mit45 79 148 (141–160) 3.3 Ascla3 (Teupser et al., 2006)
4 (B6.129-Apoe−/− × C3H.129-Apoe−/−) F2 D4Mit111 22 (3–50) 52 (10–102) 3.0 (Wang et al., 2003b)
(SM × NZB) F2 D4Mit44 29 (18–51) 59 (46–104) 3.6 Ath8 (Korstanje et al., 2004)
(A × B6.129-Apoe−/−) F2 4–135 Mb 76 143 (136–154) 4.6 Ishimori et al, unpublished
(MOLF × B6-Ldlr−/−) × B6-Ldlr−/− D4Mit127 78 (66–81) 149 (136–151) 6.2 Athsq1 (Welch et al., 2001)
5 (AKR.129-Apoe−/− × DBA/2.129-Apoe−/−) RpF2 rs13478585 84 147 (130–139) 3.4 Ath24 (Smith et al., 2006)
6 (CAST × B6) F2 D6Mit256 61 (46–71) 127 (105–144) 6.7 Artles (Mehrabian et al., 2001)
(MOLF × B6-Ldlr−/−) × B6-Ldlr−/− D6Mit110 64 (52–70) 136 (115–143) 6.7 Athsq2 (Welch et al., 2001)
7 (B6 × DBA/2) F2 D7Mit193 25 51 (33–68) 3.7 Aorls2 (Colinayo et al., 2003)
A × B and B × A RI lines Tyr 44 (20–50) 87 (41–100) Ath3 (Stewart-Phillips et al., 1989)
8 (B6 × A) F2 8–54 Mb 22 36 (31–67) 2.8 Ishimori et al, unpublished
(B6 × DBA/2) F2 D8Mit41 29 49 (39–88) 3.4 (Colinayo et al., 2003)
(A × B6.129-Apoe−/−) F2 8–109 Mb 60 120 (106–129) 2.0 Ishimori et al, unpublished
9 (B6 × A) F2 9–48 Mb 25 43 (34–63) 4.1 Ishimori et al, unpublished
SWR (SWR × SJL) D9Mit330 26 45 (36–66) Svenson et al, unpublished
(A × B6.129-Apoe−/−) F2 9–64 Mb 42 74 (60–98) 3.7 Ishimori et al, unpublished
(B6.129-Apoe−/− × C3H.129-Apoe−/−) F2 D9Mit156 42 74 (60–98) 4.1 Ath22 (Su et al., 2006)
10 (B6 × 129) F2 D10Mit213 10 (5–40) 19 (12–74) Ath20g (Ishimori et al., 2004)
(B6.129-Apoe−/− × FVB.129-Apoe−/−) F2 D10Mit213 11 (0–29) 20 (0–51) 5.1 Ath11 (Dansky et al., 2002)
(A × B6.129-Apoe−/−) F2 10–27 Mb 12 22 (7–29) 2.8 Ishimori et al, unpublished
(B6.129-Ldlr −/− × FVB.129-Ldlr −/−) RpF2 D10Mit16 16 21 (14–43) 13.1 Ascla1 (Teupser et al., 2006)
(B6 × A) F2 10–27 Mb 20 26 (18–55) 3.9 Ishimori et al, unpublished
(B6 × DBA/2) F2 D10Mit42 30 (14–45) 55 (20–88) 4.5 Aorls1 (Colinayo et al., 2003)
(B6 × 129) F2 D10Mit31 34 (30–36) 67 (55–68) 6.6 Ath17 (Ishimori et al., 2004)
11 (B6.129-Apoe −/− × C3H.129-Apoe −/−) F2 D11Mit236 20 44 (20–56) 2.4 (Su et al., 2006)
(B6 × 129) F2 D11Mit333 60 (55–70) 99 (94–113) Ath19g (Ishimori et al., 2004)
12 (B6-db/db × BKS) F2 D12Mit49 3 (2–4) 13 (9–15) 2.5 Ath6 (Mu et al., 1999)
(B6.129-Ldlr−/− × FVB.129-Ldlr−/−) RpF2 D12Mit82 3 13 (0–39) 3.9 Ascla5 (Teupser et al., 2006)
(B6 × 129) F2 D12Mit243 16 (13–17) 36 (32–38) 3.7 Ath18 (Ishimori et al., 2004)
(B6.129-Ldlr−/− × FVB.129-Ldlr−/−) RpF2 D12Mit189 24 (0–34) 55 (0–79) 4.8 Ascla6 (Teupser et al., 2006)
SWR × (SWR × SJL), SWR × SJL RI D12Mit158 38 (35–40) 85 (81–86) Ath7 Svenson et al, unpublished
(B6 × 129) F2 D12Mit7 50 (10–70) 103 (27–119) Ath21g (Ishimori et al., 2004)
13 (AKR.129-Apoe−/− × DBA/2.129-Apoe−/−) RpF2 rs13481782 26 43 (33–67) 2.8 Ath25 (Smith et al., 2006)
14 (B6.129-Apoe−/− × FVB.129-Apoe−/−) F2 D14Mit60 15 (10–40) 45 (28–70) 2.5 Ath13 (Dansky et al., 2002)
(A × B6.129-Apoe−/−) F2 14–52 Mb 22 55 (31–69) 2.6 Ishimori et al, unpublished
15 (AKR.129-Apoe−/− × DBA/2.129-Apoe−/−) RpF2 rs13482467 14 20 (10–29) 3.3 Ath22 (Smith et al., 2006)
16 (B6.129-Apoe−/− × FVB.129-Apoe−/−) F2 D16Mit103 22 29 (13–45) 2.5 (Dansky et al., 2002)
17 (AKR.129-Apoe−/− × DBA/2.129-Apoe−/−) RpF2 rs13482966 20 36 (33–54) 4.3 Ath26 (Smith et al., 2006)
18 (B6.129-Ldlr−/− × FVB.129-Ldlr−/−) F2 D18Mit23 21 44 (21–57) 3.1 (Teupser and Breslow, 2004)
(A × B6.129-Apoe−/−) F2 18–52 Mb 22 46 (23–59) 2.5 Ishimori et al, unpublished
(AKR.129-Apoe−/− × DBA/2.129-Apoe−/−) RpF2 rs13483316 22 41 (39–57) 3.6 Ath27 (Smith et al., 2006)
19 (B6.129-Apoe−/− × FVB.129-Apoe−/−) F2 D19Mit120 41 (6–54) 42 (12–58) 3.8 Ath16 (Dansky et al., 2002)
? A × B RI, B × A RI Ath2 (Paigen, 1995)
a

RI, recombinant inbred strains; F2, intercross; RpF2, reciprocal F2—both strains were used as female and male parental strains, and the F2s were combined for analysis.

b

Peak marker. The non-MIT markers are all SNP markers with their positions (for example, 1–169 Mb means a SNP on Chr 1, at 169 Mb).

c

cM, peak centimorgan. Genetic distances were retrieved from MGI at http://www.informatics.jax.org. CI: 95% confidence interval.

d

Mb, megabase, derived from the physical positions (Ensembl NCBI m36, Gene build April 2006) of the markers at the corresponding cM position. In the absence of information on CI in cM, peak ± 10 cM is used instead.

e

LOD, logarithm of the odds ratio